Alto Neuroscience Stock

altoneuroscience.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $101.8MM

Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.

Register for Details

For more details on financing and valuation for Alto Neuroscience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Alto Neuroscience.

Register Today

Team

Management Team

Amit Etkin, MD, PhD
Founder and Chief Executive Officer
Dan Segal
Co-Founder and Chief Strategy Officer
Adam Savitz, MD, PhD
Chief Medical Officer
Wei Wu, PhD
Co-Founder and Chief Data Science Officer
Nick Smith
Chief Financial Officer
MIkael Eliasson, MD, PhD
Chief Operating Officer

Board Members

Gwill York, MBA
Lighthouse Capital Partners
Aaron Weaver
Apeiron Investment Group
Jeff Chen, PhD
Alkeon Capital Management
Christopher Nixon Cox, JD
Lightswitch Capital

Other companies like Alto Neuroscience in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Alto Neuroscience Announces $35 Million Series B Financing
Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital, with participation from other new investors including Sobrato Capital, Novartis Pharma AG, Valor Equity Partners, Korify Capital, Vine Ventures, and Gaingels.
Updated on: Sep 27, 2023